SureTrader
Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

Bottom Line

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
noretreat Member Profile
 
Followed By 120
Posts 10,310
Boards Moderated 2
Alias Born 01/06/10
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 1/11/2018 4:35:53 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/27/2017 3:08:40 PM
Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) "Edgar (US Regulatory)" - 11/13/2017 10:03:05 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/8/2017 4:04:57 PM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 9/22/2017 6:02:17 AM
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 9/11/2017 12:47:10 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 9/11/2017 6:04:38 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/11/2017 6:04:37 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/6/2017 6:27:18 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/6/2017 6:24:45 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 8/8/2017 4:18:08 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 8/8/2017 4:17:33 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 8/8/2017 4:17:00 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 8/8/2017 4:16:36 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/13/2017 4:04:10 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/7/2017 4:19:05 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/9/2017 4:09:09 PM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 4/28/2017 12:50:45 PM
Bahamas Development Corp. (OTC Pink: BDCI) $2.4 Million in Sales and 10% Quarterly Growth – Issues Guidance "InvestorsHub NewsWire" - 4/17/2017 7:03:27 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/31/2017 4:25:24 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 3/29/2017 4:13:08 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/27/2017 11:29:27 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/16/2017 7:01:38 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 2/9/2017 4:04:17 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/9/2017 9:39:24 AM
noretreat   Wednesday, 01/03/18 07:43:11 AM
Re: JUST 10-11-12 post# 211216
Post # of 213669 
Bottom Line

Rinse with Brilacidin and you are less likely to get severe oral mucositis. If you do get severe OM, it will come later in treatment. But if you do get it, it has to run its course and the duration MAY be no shorter than otherwise.

Given this option, I think most patients would opt to use Brilacidin oral rinse.

Results of this study are encouraging. There is considerable new funding floating around in terms of venture capital and on Big Pharma balance sheets. The stars are aligning Leo. It is time to accept terms and advance your company. It is unlikely that there will EVER be a better time to move forward with what ever partnership you can find for Brilacidin OM.

Do it!


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist